

MEDICINOVA INC  
Form 8-K  
February 27, 2009

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**  
**WASHINGTON, DC 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the**  
**Securities Exchange Act of 1934**

Date of report (Date of earliest event reported): February 25, 2009

**MEDICINOVA, INC.**

(Exact name of Registrant as Specified in Its Charter)

**DELAWARE**  
(State or Other Jurisdiction  
of Incorporation)

**001-33185**  
(Commission  
File Number)

**33-0927979**  
(IRS Employer  
Identification No.)

**4350 LA JOLLA VILLAGE DRIVE, SUITE 950, SAN DIEGO, CA**  
(Address of Principal Executive Offices)

**92122**  
(Zip Code)

Registrant's telephone number, including area code: (858) 373-1500

Edgar Filing: MEDICINOVA INC - Form 8-K

**Not Applicable**

**(Former Name or Former Address, if Changed Since Last Report)**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

- .. Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  
- .. Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  
- .. Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  
- .. Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 1.01. Entry into a Material Definitive Agreement**

As disclosed in a Current Report on Form 8-K filed by MediciNova, Inc. ( MediciNova ) on January 21, 2009, MediciNova previously has entered into a Credit Line Account Application and Agreement for Organizations and Businesses (the Credit Line Agreement ) with UBS Bank USA ( UBS Bank ) on January 14, 2009 that provides MediciNova with an uncommitted, demand revolving line of credit of up to 75% of the market value, as determined by UBS Bank in its sole discretion, of MediciNova s auction rate securities that MediciNova has pledged as collateral. On February 25, 2009, UBS Bank increased MediciNova s availability under the Credit Line Agreement by \$2,200,000 to \$18,100,000. MediciNova subsequently borrowed an additional \$2,200,000 under the Credit Line Agreement, bringing the total amount outstanding under the facility to \$18,100,000.

**Item 2.03. Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant**

- (a) See Item 1.01 herein for information regarding the increase in availability under the Credit Line Agreement and MediciNova s subsequent drawdown under the facility.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, MediciNova has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**MEDICINOVA, INC.**

Date: February 26, 2009

By: /s/ Shintaro Asako  
Name: Shintaro Asako  
Title: Chief Financial Officer